Nasdaq Warns Pressure BioSciences of Second Non-compliance | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences has received notice from Nasdaq that it is not in compliance with a requirement to remain listed on the exchange.

In a document filed with the US Securities and Exchange Commission on Friday, Pressure Bio said that on Aug. 15, Nasdaq had notified it of its failure to comply with a listing requirement calling for a minimum bid price of $1 per share for 30 consecutive business days.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.